NCT02591160View on ClinicalTrials.gov

Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 13, 2017

Study Completion Date

September 13, 2017

Conditions
Hyperparathyroidism
Interventions
PROCEDURE

HCTZ cessation

Patients will stop taking their HCTZ for 3 months

Trial Locations (1)

65212

University of Missouri, Columbia

All Listed Sponsors
lead

University of Missouri-Columbia

OTHER

NCT02591160 - Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism | Biotech Hunter | Biotech Hunter